Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovation Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Focusing on unmet needs in CNS and oncology, Ovation Pharmaceuticals Inc. will acquire marketed drugs and late-stage candidates that don't represent a big enough payoff to their current manufacturers. The company plans to boost its acquisitions' value by developing new dosages, new formulations and new treatment indications, then add creative sales and marketing muscle to bring its products to the light of day.
Advertisement

Related Content

The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Chester Valley Pharmaceuticals Inc.
Chester Valley Pharmaceuticals Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel